Navigation Links
Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate
Date:3/22/2011

TUESDAY, March 22 (HealthDay News) -- The death rate of patients with chronic myeloid leukemia who took Gleevec and were in remission two years after treatment was similar to the death rate in the general population, a new study shows.

Italian researchers collected data on 832 patients who were taking Gleevec (imatinib) for up to eight years and found that 20 patients died during the follow-up period. That death rate of 4.8 percent, however, is similar to what would be expected in the general population.

Only six deaths were related to chronic myeloid leukemia (CML), the researchers noted.

Serious adverse events such as cardiovascular and digestive problems were reported in 139 patents, but only 27 cases (19 percent) were considered to be related to Gleevec, according to the study.

Other adverse events frequently connected to Gleevec included muscle cramps, weakness, edema, skin fragility, diarrhea, and tendon or ligament lesions. Nineteen patients (2.3 percent) stopped taking Gleevec due to side effects, with half switching to another drug.

Patients taking Gleevec "frequently suffer from side effects that are non-serious but can nonetheless reduce their quality of life," the researchers wrote.

The study authors disclosed no conflicts of interest, noting that their independence from pharmaceutical interests was a major strength of the study.

The researchers also noted the "importance of a good patient-provider relationship, in which side effects are easily communicated and addressed to reduce/avoid non-compliance."

In an accompanying editorial, Dr. B. Douglas Smith of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, noted "the astounding effect [imatinib] has had on the clinical course of this disease."

However, he wrote that many patients in the study had been treated first with interferon, which may have been a factor in their remissions. For this reason, he concluded, "a careful analysis of the two groups" -- patients who had taken interferon and those who had not -- "might help shed light on this issue."

The study appears online March 22 in the Journal of the National Cancer Institute.

More information

The American Cancer Society has more about chronic myeloid leukemia.

-- Robert Preidt

SOURCE: Journal of the National Cancer Institute, March 22, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Less Is More With Acute Myeloid Leukemia Drug
2. When leukemia returns, gene that mediates response to key drug often mutated
3. A small subset of normal white blood cells gives rise to a rare leukemia, study shows
4. Scientists bioengineer a protein to fight leukemia
5. Southampton scientists begin patient trials of new leukemia cancer vaccine
6. Discovery of a gene associated with a leukemia mostly affecting children
7. MicroRNA-TP53 circuit connected to chronic lymphocytic leukemia
8. Gene Activity May Affect Acute Myeloid Leukemia Outcome
9. Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients
10. Researchers make critical leukemia stem cell discovery
11. New therapies and gene target advance the treatment and understanding of hard-to-treat leukemias
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs included on ... health systems in the nation and help their organizations navigate the challenges in ... been instrumental in developing successful hospital and health system strategy. , Becker's Hospital ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Technique, technique, technique ... injury when either lifting weights for strength training and exercise or simply lifting heavy ... . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting anything ...
(Date:5/23/2017)... ... 23, 2017 , ... MDLand International (MDLand), a leading Electronic ... its iClinic V12.2 solution has achieved approval from National Center for Quality Assurance ... standards which emphasize team-based care with a significant focus on the care management ...
(Date:5/23/2017)... ... 2017 , ... Allegheny Health Network and the Alexis Joy ... Women’s Behavioral Health at West Penn Hospital , a unique facility that will ... pregnancy-related depression. Construction of the Center is underway with a scheduled opening in ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, ... remained steady since 2009, according to a Workers Compensation Research Institute (WCRI) study, ... Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity ...
Breaking Medicine News(10 mins):
(Date:5/11/2017)... May 11, 2017  Thornhill Research Inc. ( ... awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract ... Canadian Commercial Corporation (CCC) ( Ottawa, Ontario, ... to administer general anesthesia to patients requiring emergency ... "The US Marine Corps have been a longtime ...
(Date:5/10/2017)... -- Radiology has become the number one diagnostic tool ... to the number one ranking as a result.  More ... as the most complete and reliable method for clinical ... pain an MRI may confirm a suspected herniated disc ... entirely different treatment protocols.  In these circumstances, patients need ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
Breaking Medicine Technology: